Table 1

Demographic, clinicopathologic characteristics and concentration of urinary proteins in the study cohort
Non-cancer (%) Cancer (%)
N=63 N=64
Median Age (range, y) 60 (30-81) 69.5 (22-90)
Male : Female ratio 55 : 8 55 : 9
Race
    White 41 (65) 58(91)
    African American 8 (13) 0(0)
    Other 14 (22) 6 (9)
Tobacco use 25 (40) 54 (84)
Gross hematuria 0 (0) 47 (73)
Suspicious/positive cytology 1 (2) 18 (28)
Median follow-up (months) 11.5 12.0
Clinical stage
    Tis^ n/a 6(9)
    Ta n/a 15(23)
    T1 n/a 9 (14)
    T2 n/a 31(48)
    T3 n/a 4 (6)
    T4 n/a 2 (3)
    N+ ~ n/a 3 (5)
Grade
    Low n/a 9(14)
    High n/a 55(86)
Urinary Proteins Median (range) Median (range)
    IL-8 (pg/ml) 0(0 - 134.33) 128.43 (0 - 17140.2)
    MMP–9 (ng/ml) 0 (0 – 14.25) 0.95 (0 – 1002.6)
    Syndecan (ng/ml) 40.67(0 - 199.55) 31.81(0 - 335.18)
    BTA-Trak (U/ml) 13.13(0.5 - 36.87) 179.33 (0 - 24865.4)
    Hemoglobin (ng/ml) 0(0 - 125.92) 8.73 (0 - 130367.5)
Mean
    +
SD
Mean
    +
SD
    IL-8 (pg/ml) 05.02 ± 20.99 1335.07 ±3495.26
    MMP–9 (ng/ml) 0.35 ±1.83 46.76 ±142.16
    Syndecan (ng/ml) 49.10 ± 42.09 55.04 ± 74.88
    BTA-Trak (U/ml) 14.66 ± 8.05 1630.5 ± 3954.5
    Hemoglobin (ng/ml) 2.63±15.97 4451.3±22814.4

^, 4 subjects with concomitant cis had T1 (n=2) and T2 (n=2) disease.

~, Subjects with T2 (n=1), T3 (=1) and T4 (n=1) disease and node positive.

Urquidi et al.

Urquidi et al. BMC Urology 2012 12:12   doi:10.1186/1471-2490-12-12

Open Data